BACKGROUND

- Oral antineoplastic agents (OAAs) have treatment benefits at a rapid pace and are changing the primary practice of the treatment of many cancers.
- Evidence to date supports fewer toxics to be included in the treatment in order to reduce the number of toxicities that patients may experience.
- Emerging licensure on an ever-increasing amount of agents, mostly treated to breast cancer, makes the selection of a treatment even more challenging.
- Pain management is a significant challenge that needs to be addressed.
- The more patients experience pain, the more their quality of life may be impacted. The focus should be on understanding the approach on pain management.

OBJECTIVE

- To evaluate the role of monitoring and addressing patient-reported outcomes (PROs) in measuring risk factors for non-adherence.
- To determine the key domains that are most effective in the identification of non-adherence risk.

METHODS

- Studies measuring adherence with OAAs were included if they involved the use of OAAs and PROs/Questionnaires to identify non-adherence risk.
- Studies were excluded if they involved the use of dispositional measures.
- Studies were excluded if they involved the use of dispositional measures.
- Studies were excluded if they involved the use of dispositional measures.
- Studies were excluded if they involved the use of dispositional measures.

RESULTS

- Of 100 abstracts reviewed, 11 studies met all study inclusion/exclusion criteria.
- Nine studies (82%) used at least one validated PRO instrument and 7 studies (64%) used at least one study-specific questionnaire.
- In all 11 studies, PRO scores were found to be significantly lower among patients who had lower adherence.
- PRO scores were significantly lower among patients who had lower adherence.
- PRO scores were significantly lower among patients who had lower adherence.
- PRO scores were significantly lower among patients who had lower adherence.
- PRO scores were significantly lower among patients who had lower adherence.

Table 1: Details of Studies Involving Oral Antineoplastic Agents (OAAs) Implementing PROs and Questionnaires in Order to Identify Nonadherence Predictors: Specific Instruments, Domains, and Key Characteristics

<table>
<thead>
<tr>
<th>Country</th>
<th>Study Type</th>
<th>Study Design</th>
<th>Number of Participants</th>
<th>PROs Measured</th>
<th>Non-Adherence Risk Factors</th>
<th>Other Non-Adherence Predictors</th>
</tr>
</thead>
<tbody>
<tr>
<td>United States</td>
<td>Prospective</td>
<td>Survey</td>
<td>100</td>
<td>BMQ, MMAS, SIMS</td>
<td>Social support, trust</td>
<td>Side-effects, disease severity</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>Prospective</td>
<td>Survey</td>
<td>100</td>
<td>BMQ, MMAS, SIMS</td>
<td>Social support, trust</td>
<td>Side-effects, disease severity</td>
</tr>
<tr>
<td>Germany</td>
<td>Prospective</td>
<td>Survey</td>
<td>100</td>
<td>BMQ, MMAS, SIMS</td>
<td>Social support, trust</td>
<td>Side-effects, disease severity</td>
</tr>
<tr>
<td>Italy</td>
<td>Prospective</td>
<td>Survey</td>
<td>100</td>
<td>BMQ, MMAS, SIMS</td>
<td>Social support, trust</td>
<td>Side-effects, disease severity</td>
</tr>
</tbody>
</table>

Figure 1. Tumor Types Evaluated

Figure 2. PRO Instruments Used

CONCLUSIONS

- PROs for non-adherence measurement by patients reports oral anti-cancer treatments adherence.
- PROs are used to evaluate the level of non-adherence treatment adherence.
- PROs are used to evaluate the level of non-adherence treatment adherence.
- PROs are used to evaluate the level of non-adherence treatment adherence.
- PROs are used to evaluate the level of non-adherence treatment adherence.

REFERENCES


Figure 3. PRO Instrument and Questionnaire Domains Measured

Figure 4. PRO Instruments Used

Figure 5. PRO Instrument and Questionnaire Domains Measured

Figure 6. PRO Instruments Used

Figure 7. PRO Instrument and Questionnaire Domains Measured

Figure 8. PRO Instruments Used

Figure 9. PRO Instrument and Questionnaire Domains Measured

Figure 10. PRO Instruments Used

Figure 11. PRO Instrument and Questionnaire Domains Measured

Figure 12. PRO Instruments Used

Figure 13. PRO Instrument and Questionnaire Domains Measured

Figure 14. PRO Instruments Used

Figure 15. PRO Instrument and Questionnaire Domains Measured

Figure 16. PRO Instruments Used

Figure 17. PRO Instrument and Questionnaire Domains Measured

Figure 18. PRO Instruments Used

Figure 19. PRO Instrument and Questionnaire Domains Measured

Figure 20. PRO Instruments Used

Figure 21. PRO Instrument and Questionnaire Domains Measured

Figure 22. PRO Instruments Used

Figure 23. PRO Instrument and Questionnaire Domains Measured

Figure 24. PRO Instruments Used

Figure 25. PRO Instrument and Questionnaire Domains Measured

Figure 26. PRO Instruments Used

Figure 27. PRO Instrument and Questionnaire Domains Measured

Figure 28. PRO Instruments Used

Figure 29. PRO Instrument and Questionnaire Domains Measured

Figure 30. PRO Instruments Used

Figure 31. PRO Instrument and Questionnaire Domains Measured

Figure 32. PRO Instruments Used

Figure 33. PRO Instrument and Questionnaire Domains Measured

Figure 34. PRO Instruments Used

Figure 35. PRO Instrument and Questionnaire Domains Measured

Figure 36. PRO Instruments Used

Figure 37. PRO Instrument and Questionnaire Domains Measured

Figure 38. PRO Instruments Used

Figure 39. PRO Instrument and Questionnaire Domains Measured

Figure 40. PRO Instruments Used

Figure 41. PRO Instrument and Questionnaire Domains Measured

Figure 42. PRO Instruments Used

Figure 43. PRO Instrument and Questionnaire Domains Measured

Figure 44. PRO Instruments Used

Figure 45. PRO Instrument and Questionnaire Domains Measured

Figure 46. PRO Instruments Used

Figure 47. PRO Instrument and Questionnaire Domains Measured

Figure 48. PRO Instruments Used

Figure 49. PRO Instrument and Questionnaire Domains Measured

Figure 50. PRO Instruments Used

Figure 51. PRO Instrument and Questionnaire Domains Measured

Figure 52. PRO Instruments Used

Figure 53. PRO Instrument and Questionnaire Domains Measured

Figure 54. PRO Instruments Used

Figure 55. PRO Instrument and Questionnaire Domains Measured

Figure 56. PRO Instruments Used

Figure 57. PRO Instrument and Questionnaire Domains Measured

Figure 58. PRO Instruments Used

Figure 59. PRO Instrument and Questionnaire Domains Measured

Figure 60. PRO Instruments Used

Figure 61. PRO Instrument and Questionnaire Domains Measured

Figure 62. PRO Instruments Used

Figure 63. PRO Instrument and Questionnaire Domains Measured

Figure 64. PRO Instruments Used

Figure 65. PRO Instrument and Questionnaire Domains Measured

Figure 66. PRO Instruments Used

Figure 67. PRO Instrument and Questionnaire Domains Measured

Figure 68. PRO Instruments Used

Figure 69. PRO Instrument and Questionnaire Domains Measured

Figure 70. PRO Instruments Used

Figure 71. PRO Instrument and Questionnaire Domains Measured

Figure 72. PRO Instruments Used

Figure 73. PRO Instrument and Questionnaire Domains Measured

Figure 74. PRO Instruments Used

Figure 75. PRO Instrument and Questionnaire Domains Measured

Figure 76. PRO Instruments Used

Figure 77. PRO Instrument and Questionnaire Domains Measured

Figure 78. PRO Instruments Used

Figure 79. PRO Instrument and Questionnaire Domains Measured

Figure 80. PRO Instruments Used

Figure 81. PRO Instrument and Questionnaire Domains Measured

Figure 82. PRO Instruments Used

Figure 83. PRO Instrument and Questionnaire Domains Measured

Figure 84. PRO Instruments Used

Figure 85. PRO Instrument and Questionnaire Domains Measured

Figure 86. PRO Instruments Used

Figure 87. PRO Instrument and Questionnaire Domains Measured

Figure 88. PRO Instruments Used

Figure 89. PRO Instrument and Questionnaire Domains Measured

Figure 90. PRO Instruments Used

Figure 91. PRO Instrument and Questionnaire Domains Measured

Figure 92. PRO Instruments Used

Figure 93. PRO Instrument and Questionnaire Domains Measured

Figure 94. PRO Instruments Used

Figure 95. PRO Instrument and Questionnaire Domains Measured

Figure 96. PRO Instruments Used

Figure 97. PRO Instrument and Questionnaire Domains Measured

Figure 98. PRO Instruments Used

Figure 99. PRO Instrument and Questionnaire Domains Measured

Figure 100. PRO Instruments Used